Piper Jaffray Says BioMarin (BMRN) Could Be Taken Out for $52-$70/Share
Tweet Send to a Friend
Get Alerts bmrn Hot Sheet
Price: $64.01 -0.76%
Rating Summary:
10 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
10 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade bmrn Now!
With shares of BioMarin (Nasdaq: BMRN) modestly higher Tuesday afternoon amid chatter GSK could be eying the company, Piper Jaffray's Ian Somaiya issued some commentary on the rumor.
Although the analyst believes a takeover of the company is unlikely until results from a key clinical trial are released during the second half of this year, Somaiya placed a potential purchase price in the range of $52-$70 per share. The analyst said he sees multiple bidders being involved.
With BioMarin shares up 1.7 percent to $36.27 at last check, Somaiya's estimate implies a premium of about 43 to 93 percent.
Piper Jaffray maintains an Overweight rating and $43 price target on shares of BioMarin.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Although the analyst believes a takeover of the company is unlikely until results from a key clinical trial are released during the second half of this year, Somaiya placed a potential purchase price in the range of $52-$70 per share. The analyst said he sees multiple bidders being involved.
With BioMarin shares up 1.7 percent to $36.27 at last check, Somaiya's estimate implies a premium of about 43 to 93 percent.
Piper Jaffray maintains an Overweight rating and $43 price target on shares of BioMarin.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Accretion to Actavis (ACT) from Warner Chilcott (WCRX) Deal Could Be Substantial - Jefferies
- Needham & Company Remains on Sidelines wth Applied Materials (AMAT) Post Q2
Create E-mail Alert Related Categories
Analyst Comments, RumorsRelated Entities
Piper Jaffray
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
